Effects of two combined monophasic and triphasic ethinylestradiol/ gestodene oral contraceptives on natural inhibitors and other hemostatic variables

European Journal of Contraception and Reproductive Health Care

Volumn 2, Issue 1, 1997, Pages 31-38

  Creatsas, G ^a,c   Kontopoulou Griva, I ^b   Deligeoroglou, E ^a   Digenopoulou, L ^b   Tsangaris, A ^a   Kallipolitis, G ^a   Milingos, S ^a   Michalas, S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Hemostasis; Hemostatic variables; Natural inhibitors; Oral contraceptives; Venous thromboembolism

Indexed keywords

ANTITHROMBIN III; ESTRADIOL DERIVATIVE; ETHINYLESTRADIOL; FIBRINOGEN; GESTODENE; LUPUS ANTICOAGULANT; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PREGNANE DERIVATIVE; PROGESTERONE DERIVATIVE; PROTEIN C;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HEMOSTASIS; HUMAN; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; TIME;

ADOLESCENT; ADULT; ANTITHROMBIN III; CONTRACEPTIVES, ORAL, COMBINED; CONTRACEPTIVES, ORAL, SYNTHETIC; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; FIBRINOGEN; HEMOSTASIS; HUMANS; LUPUS COAGULATION INHIBITOR; NORPREGNENES; PLASMINOGEN; PROGESTERONE CONGENERS; PROTEIN C; PROTHROMBIN TIME; TIME FACTORS;

EID: 0031083611     PISSN: 13625187     EISSN: None     Source Type: Journal    
DOI: 10.1080/13625189709049932     Document Type: Article

References (20)

1. Winkler UH. Role of screening for vascular disease in pill users: the hemostatic system. In Hannaford PC, Webb AMC, eds. Evidence-guided Prescribing of the Pill. Carnforth, UK: Parthenon Publishing, 1996; 109-20
2. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case case control study. Lancet 1995; 346: 1575-82
3. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low-estrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8
4. The Writing Committee for the Second European Conference on Sex Steroids and Metabolism. Combined oral contraceptives and cardiovascular disease. Consensus statement issued after the second European conference on sex steroids and metabolism, Amsterdam 1985. Gynecol Endocrinol 1996; 10: 1-5
5. Fotherby U. Are changes in haemostatical factors and cardiovascular risk during oral contraceptive use dose-related? Fertil Control Rev 1994; 3: 11-15
6. Prasad RNV, Oei PL. The epidemiology of venous disease in oral contraceptive users. Fertil Control Rev 1994; 3: 15-18
7. Spitzer WO, Lewis MA, Heinemann LAJ, et al. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-7
8. The Estradiol Clotting Factors Study Group. Effect of hemostasis of hormone replacement therapy with transdermal estradiol and oral segmental medroxy-progesterone acetate: A 1-year, double blind placebo controlled study. Thromb Haemost 1996; 75: 476-80
9. Greaves M, Preston FE. Clinical and laboratory aspects of thrombophilia. In Pollar L, ed. Recent Advances in Blood Coagulation. 1991; 119-40
10. Jespersen J, Petersen K, Skouby S. Effects of newer oral contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. AmJ Obstet Gynecol 1990; 163; 396-403
11. Beller FK, Ebert C. Effects of oral contraceptives on blood coagulation. A review. Obstet Gynecol Surv 1985; 40: 425-36
12. Bonnar J. Coagulation effects of oral contraceptives. Am J Obstet Gynecol 1987; 157: 1042-8
13. Bruni V, Abbate S, Pinto S, et al. Effects of gestodene on hemostasis. Proceedings of the 1st International Congress on Gynecological Endocrinology. Gynecological Endocrinology Carnforth, UK: Parthenon Publishing, 1987: 523-32
14. Malm J, Laurell M, Dahlback B. Changes in the plasma levels of vitamin K-dependent protein C and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988; 68: 437-43
15. Pabinger I, Schneider B, and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III, protein C and protein S deficiency taking oral contraceptives. Thromb Haemost 1994; 71: 548-52
16. Kluft C. Oral contraceptives and hemostasis. Gynecol Endocrinol 1996: 10(Suppl): 49-57
17. Helmerhorst FM, Bloemenkamp KWM, Breit E, et al. Factor V Leiden mutation and contraception. Gynecol Endocrinol 1996; 10(Suppl): 85-7
18. Osternd B, Robertson R, Asvang GB, Thijssen F. Resistance to activated protein C is reduced in women using oral contraceptives. Blood Coag Fibrinolys 1994; 5: 853-4
19. Mannucci PM, Tripodi A, Bottasso B, et al. Markers of procoagulant imbalance in patients with inherited thrombophyllic syndromes. Thromb Haemost 1992; 67: 200-2
20. Bonen B, Bes G, Pelaez H, et al. D-Dimers thrombin-antithrombin III complexes and prothrombin fragments 1 + 2 diagnostic value in clinically suspected deep vein thrombosis. Thromb Haemost 1991; 65: 28-32